Cargando…

Semi‐Mechanism‐Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor Vismodegib

Vismodegib, approved for the treatment of advanced basal cell carcinoma, has shown unique pharmacokinetic (PK) nonlinearity and binding to α1‐acid glycoprotein (AAG) in humans. A semi‐mechanism‐based population pharmacokinetic (PopPK) model was developed from a meta‐dataset of 225 subjects enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, T, Wang, B, Gao, Y, Dresser, M, Graham, RA, Jin, JY
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716579/ https://www.ncbi.nlm.nih.gov/pubmed/26783504 http://dx.doi.org/10.1002/psp4.12039

Ejemplares similares

The dawn of hedgehog inhibitors: Vismodegib
por: Sandhiya, Selvarajan, et al.
Publicado: (2013)

Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib
por: Hehlgans, Stephanie, et al.
Publicado: (2018)

Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole
por: Freitas, Raíza Dias, et al.
Publicado: (2020)

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
por: Catenacci, Daniel V.T., et al.
Publicado: (2015)

Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds
por: Yang, Hyekyung, et al.
Publicado: (2015)

NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations
por: Zhao, Jie, et al.
Publicado: (2014)

Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms
por: Singh, Brahma N., et al.
Publicado: (2011)

A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib
por: Malhi, Vikram, et al.
Publicado: (2016)

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
por: De Jesus-Acosta, Ana, et al.
Publicado: (2019)

Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib‐resistance
por: Gampala, Silpa, et al.
Publicado: (2021)

Hedgehog signaling pathway: A novel target for cancer therapy: Vismodegib, a promising therapeutic option in treatment of basal cell carcinomas
por: Abidi, Afroz
Publicado: (2014)

Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome
por: Booms, Patrick, et al.
Publicado: (2015)

Pilomatricomas secondary to treatment with vismodegib
por: Magdaleno-Tapial, Jorge, et al.
Publicado: (2018)

Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma
por: Aditya, Suruchi, et al.
Publicado: (2013)

Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression
por: Petrirena, Gregorio J., et al.
Publicado: (2018)

A case of hepatotoxicity associated with vismodegib
por: Ly, Priscilla, et al.
Publicado: (2018)

Rare bone toxicity associated with vismodegib
por: Ciciarelli, Valeria, et al.
Publicado: (2020)

Evaluation of Hedgehog Pathway Inhibition on Nevoid Basal Cell Carcinoma Syndrome Fibroblasts and Basal Cell Carcinoma-Associated Fibroblasts: Are Vismodegib and Sonidegib Useful to Target Cancer-Prone Fibroblasts?
por: Eibenschutz, Laura, et al.
Publicado: (2021)

Vismodegib: the Proof of Concept in Basal Cell Carcinoma
por: Berrada, Narjiss, et al.
Publicado: (2014)

Analysis of Longitudinal‐Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models
por: Lu, Tong, et al.
Publicado: (2020)

Medical marijuana for the treatment of vismodegib-related muscle spasm
por: Yuan, Joyce T., et al.
Publicado: (2017)

Clues to primary vismodegib resistance lie in histology and genetics
por: Sun, Qisi, et al.
Publicado: (2020)

Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib
por: Su, Maxwell G., et al.
Publicado: (2020)

Treatment of Locally Advanced Basal Cell Carcinomas with Vismodegib
por: Mastronardi, Luis, et al.
Publicado: (2021)

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia
por: Mesti, Tanja, et al.
Publicado: (2022)

Clinical implications of hedgehog signaling pathway inhibitors
por: Liu, Hailan, et al.
Publicado: (2011)

Hedgehog Pathway Inhibitors against Tumor Microenvironment
por: Gampala, Silpa, et al.
Publicado: (2021)

Integrated Two‐Analyte Population Pharmacokinetic Model for Antibody–Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling
por: Lu, D, et al.
Publicado: (2016)

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
por: Cowey, C. Lance
Publicado: (2013)

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
por: Batty, Nicolas, et al.
Publicado: (2012)

Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
por: Martins, Pedro Carvalho, et al.
Publicado: (2019)

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs
por: Janssen, J. M., et al.
Publicado: (2023)

Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan
por: Chaturvedi, Nagendra K., et al.
Publicado: (2016)

Hedgehog pathway inhibitors – current status and future prospects
por: Sheikh, Asfandyar, et al.
Publicado: (2012)

The bromodomain inhibitor IBET-151 attenuates vismodegib-resistant esophageal adenocarcinoma growth through reduction of GLI signaling
por: Alvarez-Trotta, Annamil, et al.
Publicado: (2020)

Inhibitors of Hedgehog Acyltransferase Block Sonic Hedgehog Signaling
por: Petrova, Elissaveta, et al.
Publicado: (2013)

Vismodegib Identified as a Novel COX-2 Inhibitor via Deep-Learning-Based Drug Repositioning and Molecular Docking Analysis
por: Yasir, Muhammad, et al.
Publicado: (2023)

Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells
por: Kleszcz, Robert, et al.
Publicado: (2023)

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib
por: Thacker, Curtis A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_b9crjbr6d4g2kgq1utse9976t7